Back to Journals » OncoTargets and Therapy » Volume 9

Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo

Authors Zhang H, Chen R, Yang S, Liu W, Li K, Zhang H, Zhu X, Chen B

Received 8 March 2016

Accepted for publication 7 May 2016

Published 11 July 2016 Volume 2016:9 Pages 4215—4224


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Hongming Zhang,1 Runzhe Chen,2 Shaoxing Yang,3 Wenjing Liu,3 Ke Li,4 Haijun Zhang,2 Xiaoli Zhu,1 Baoan Chen2

1Department of Pulmonary Medicine, 2Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, 3Department of Pulmonary Oncology, The 307th Hospital of Chinese People’s Liberation Army, Beijing, 4Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu Province, People’s Republic of China

Abstract: Lung squamous cell carcinoma is the second-largest histological subtype of lung cancer, which is the leading cause of cancer-related death worldwide. Lobaplatin, one of the third-generation platinum compounds, has shown encouraging anticancer activity in a variety of tumors. The aim of this study was to determine the therapeutic efficacy of lobaplatin on p53-mutant lung squamous cancer cells SK-MES-1. In order to evaluate the antitumor effect of lobaplatin, several in vitro and in vivo analyses were carried out, including Cell Counting Kit-8 (CCK-8), fluorescence-activated cell sorter, Western blot, and terminal deoxynucleotidyl transferase dUTP nick end labeling. Findings showed that lobaplatin could inhibit cell proliferation and induce apoptosis of SK-MES-1 cells in vitro through both intrinsic and extrinsic apoptotic pathways in a time- and dose-dependent manner. In addition, lobaplatin could arrest cell cycle at S phase in SK-MES-1. Lobaplatin has obvious antitumor efficacy in human SK-MES-1 xenograft models; therefore, it seems to be a promising candidate in lung squamous cancer therapy.

Keywords: lobaplatin, lung squamous cell carcinoma, apoptosis, cell cycle arrest

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]